©The Author(s) 2015.
World J Crit Care Med. Aug 4, 2015; 4(3): 251-257
Published online Aug 4, 2015. doi: 10.5492/wjccm.v4.i3.251
Published online Aug 4, 2015. doi: 10.5492/wjccm.v4.i3.251
Table 2 Hemodynamics
| Landiolol | Control | |
| Heart rate, bpm | 145 ± 14a | 136 ± 21 |
| Systolic arterial pressure, mmHg | 113 ± 34a | 137 ± 39 |
| Diastolic arterial pressure, mmHg | 60 ± 17 | 66 ± 13 |
| Mean arterial pressure, mmHg | 78 ± 21 | 86 ± 28 |
| Diastolic pulmonary arterial pressure, mmHg | 19 ± 6 | 20 ± 7 |
| Cardiac output, L/min | 3.9 ± 1.7 | 5.8 ± 1.5 |
| Cardiac index, L/min per square meter | 2.5 ± 1.1a | 4.0 ± 1.3 |
| SVRI, dyne∙s/m5 per square meter | 2068 ± 795 | 1615 ± 399 |
| Arrhythmia | ||
| Paroxysmal atrial fibrillation/flutter | 34 (87%) | 13 (60%) |
| Paroxysmal atrial tachycardia | 4 (10%) | 8 (36%) |
| Paroxysmal supraventricular tachycardia | 1 (3%) | 1 (5%) |
| Concomitant drugs to control arrhythmia | ||
| Calcium-channel blocker | 3 (8%) | 5 (22%) |
| Other β blockers | 0 (0%) | 3 (14%) |
| Disopyramid phosphate | 0 (0%) | 1 (5%) |
| Amiodarone | 0 (0%) | 1 (5%) |
- Citation: Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med 2015; 4(3): 251-257
- URL: https://www.wjgnet.com/2220-3141/full/v4/i3/251.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v4.i3.251